Innovative developments in gene editing continue to expand therapeutic possibilities. The University of California and University of Vienna secured a court ruling to reconsider the CRISPR–Cas9 patent dispute, challenging earlier decisions about patent rights allocation between key inventors and the Broad Institute. Massachusetts researchers reported the first successful in vivo treatment of an infant with a fully customized base-editing CRISPR therapy for a rare metabolic disease, achieving substantial liver correction. Additional studies introduce novel CRISPR platforms, including the CRISPR-TO system for RNA localization and a lab-evolved CRISPR-associated transposase adapted for human cells, broadening the scope of gene editing precision and applicability.